基于需求的考虑,低剂量阿司匹林在心血管风险连续性的作用
Francesca Santilli1, Gerhard Albrecht2, Michael Blaha3
1Department of Medicine and Aging and Center for Advanced Studies and Technology, University of Chieti, Chieti, Italy.
American journal of preventive cardiology
|May 2, 2024
概括
尽管有指导方针的变化,阿司匹林可能对患有晚期亚临床动脉样硬化症的无症状个体有好处. 个性化风险评估是用阿司匹林优化心血管疾病 (CVD) 预防的关键.
科学领域:
- 心脏病学 心脏病学
- 预防医学 预防医学
- 临床药理学 临床药理学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,风险在连续上升.
- 阿司匹林是抗血小板治疗的基石,其在无症状患者的初级心血管疾病预防中的作用在最近的指南中被降级.
- 然而,患有高级亚临床动脉样硬化等疾病的无症状个体仍然可能受益于阿司匹林治疗,平衡心血管事件风险与出血风险.
研究的目的:
- 探索阿司匹林在无症状患者初级心血管疾病 (CVD) 预防中的作用.
- 讨论在患者管理中评估心血管和出血风险的工具和策略.
- 提供说明个性化治疗方法预防心血管疾病的假设案例.
主要方法:
- 关于在心血管疾病预防中使用阿司匹林的当前文献和临床指导方针的审查.
- 对心血管事件和出血风险评估工具的讨论.
- 介绍两个假设病例 (患有亚临床动脉样硬化的年轻患者,患有2型糖尿病的患者),以证明临床决策.
主要成果:
- 最近的试验导致阿司匹林在无症状心血管疾病预防中的指导方针被降级.
- 患有晚期亚临床动脉样硬化症的患者,如果出血风险低,可能会从预防性阿司匹林中受益.
- 个性化风险益处分析对于确定低剂量阿司匹林治疗的临床净益处至关重要.
结论:
- 个性化方法对于优化无症状患者心血管疾病 (CVD) 预防至关重要.
- 风险评估工具可以指导低剂量阿司匹林的使用,以平衡心血管疾病事件减少与出血风险.
- 假设的案例展示了如何应用这些原则来改善心血管疾病管理.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
01:23Assessment of the Cardiovascular System I: Subjective Data
322
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
322
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
496
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
496
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K